RETINOPATHY OF PREMATURITY
Clinical trials for RETINOPATHY OF PREMATURITY explained in plain language.
Never miss a new study
Get alerted when new RETINOPATHY OF PREMATURITY trials appear
Sign up with your email to follow new studies for RETINOPATHY OF PREMATURITY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could a lower dose save sight in preemies with severe eye disease?
Disease control OngoingThis study tests whether lower doses of the drug bevacizumab can effectively treat a severe form of retinopathy of prematurity (ROP) in premature infants. The condition affects blood vessels in the eye and can lead to blindness. Researchers are enrolling 77 babies with type 1 ROP…
Matched conditions: RETINOPATHY OF PREMATURITY
Phase: PHASE2 • Sponsor: Jaeb Center for Health Research • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
AI boosts eye Doctors' accuracy for preemie eye disease
Diagnosis OngoingThis study checks whether an artificial intelligence system called i-ROP DL can help eye doctors more accurately diagnose retinopathy of prematurity (ROP), a serious eye disease in premature infants. Researchers will compare how well doctors diagnose ROP with and without the AI t…
Matched conditions: RETINOPATHY OF PREMATURITY
Phase: NA • Sponsor: Siloam Vision • Aim: Diagnosis
Last updated May 26, 2026 05:23 UTC
-
Researchers track vision and development in 100 preemies after ROP treatment
Knowledge-focused OngoingThis study follows about 100 infants who were previously treated for retinopathy of prematurity (ROP), an eye condition in premature babies. Researchers want to see how their eyesight and overall development are doing over the long term. No new treatments are given—this is an obs…
Matched conditions: RETINOPATHY OF PREMATURITY
Sponsor: Regeneron Pharmaceuticals • Aim: Knowledge-focused
Last updated May 26, 2026 05:32 UTC
-
New study tracks eylea safety in preemie eyes
Knowledge-focused OngoingThis study watches Japanese babies with retinopathy of prematurity (ROP) who are already getting Eylea eye injections. Researchers will track side effects and check if the treatment stops active ROP for up to 6 months. No extra tests are done—just routine care data is collected.…
Matched conditions: RETINOPATHY OF PREMATURITY
Sponsor: Bayer • Aim: Knowledge-focused
Last updated May 26, 2026 05:23 UTC